Drugs / Anecortave Acetate
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00211406 | — | diabetic retinopathy | Manhattan Eye, Ear & Throat Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT00211419 | — | age-related macular degeneration | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00489840 | May 2007 → Jul 2010 | central serous chorioretinopathy | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT00788541 | Dec 2008 → Sep 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Terminated | No outcome recorded |
| Phase 2 | NCT00211432 | Apr 2008 → Apr 2010 | vitreous detachment | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00643669 | Feb → Apr 2008 | open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00451152 | Mar 2007 → Jul 2009 | open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00320203 | Mar 2006 → Jan 2008 | open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00315640 | Dec 2005 → Jul 2009 | eye disorder | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00211458 | Sep 2005 → Sep 2007 | macular degeneration | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00211367 | Apr 2004 → Mar 2007 | — | Manhattan Eye, Ear & Throat Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00211484 | May 2003 → Mar 2007 | age-related macular degeneration, choroidal neovascularization | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00211354 | Mar 2002 → Mar 2007 | retinal vein occlusion | Manhattan Eye, Ear & Throat Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00211471 | Mar 2002 → May 2007 | central retinal vein occlusion, diabetic retinopathy, infectious disease | Manhattan Eye, Ear & Throat Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00211328 | Mar 2002 → Mar 2007 | macular telangiectasia | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00211315 | Mar 2002 → Mar 2007 | Coats disease | Manhattan Eye, Ear & Throat Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00346866 | May 2000 → Dec 2001 | — | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00346957 | Apr 1999 → Apr 2003 | — | Alcon Research | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00691717 | Jun 2008 → Sep 2009 | ocular hypertension, open-angle glaucoma | Alcon Research | Completed | No outcome recorded |
| Phase 2/3 | NCT00705770 | May → Jul 2008 | open-angle glaucoma | Alcon Research | Withdrawn | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT00051129 | Jan 2007 → May 2008 | age-related macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00332657 | Sep 2006 → Dec 2008 | — | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00333216 | May 2005 → Dec 2008 | — | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00299507 | Mar 2005 → Apr 2008 | macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00307398 | Mar 2004 → Jan 2009 | dry age related macular degeneration | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00065728 | Jun 2003 → Oct 2008 | macular degeneration | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00058994 | Mar 2003 → Nov 2006 | age-related macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00533962 | Aug 2007 → ? | glaucoma, ocular hypertension | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT00349739 | Jan 2003 → Aug 2008 | age-related macular degeneration | University of Iowa | No longer available | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00570479 Comparator | Sep 2006 → Mar 2010 | glaucoma, posterior uveitis | Texas Retina Associates | Completed | No outcome recorded |
| Phase 3 | NCT00041483 Comparator | Jun 2002 → Aug 2005 | macular degeneration | Alcon Research | Completed | No outcome recorded |
| — | NCT00884039 Comparator | May 2009 → Aug 2010 | disease related to transplantation, ocular hypertension | Cornea Research Foundation of America | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anecortave acetate | “One new angiostatic steroid, anecortave acetate (AL-3789), may represent a breakthrough in the therapy of ocular neovascular diseases such as AMD and diabetic retinopathy.” NCT00349739 ↗ |
| Known as | AL-3789 | “One new angiostatic steroid, anecortave acetate (AL-3789), may represent a breakthrough in the therapy of ocular neovascular diseases such as AMD and diabetic retinopathy.” NCT00349739 ↗4“Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg” NCT00307398 ↗ “Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL” NCT00065728 ↗ “Active Ingredients: Anecortave Acetate (AL-3789)” NCT00570479 ↗ |
| Action | Inhibit | “Anecortave Acetate injection is considered as an attempt to control the growth of the abnormal blood vessels.” NCT00211328 ↗ |
| Route | Other | “administered as a posterior juxtascleral injection” NCT00051129 ↗ |